[go: up one dir, main page]

NZ508981A - Means and methods for monitoring nucleoside reverse transcriptase inhibitor antiretroviral therapy and guiding therapeutic decisions in the treatment of HIV/AIDS - Google Patents

Means and methods for monitoring nucleoside reverse transcriptase inhibitor antiretroviral therapy and guiding therapeutic decisions in the treatment of HIV/AIDS

Info

Publication number
NZ508981A
NZ508981A NZ508981A NZ50898199A NZ508981A NZ 508981 A NZ508981 A NZ 508981A NZ 508981 A NZ508981 A NZ 508981A NZ 50898199 A NZ50898199 A NZ 50898199A NZ 508981 A NZ508981 A NZ 508981A
Authority
NZ
New Zealand
Prior art keywords
hiv
reverse transcriptase
aids
monitoring
treatment
Prior art date
Application number
NZ508981A
Inventor
Christos J Petropoulos
Jeannette Whitcomb
Original Assignee
Virologic Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Virologic Inc filed Critical Virologic Inc
Publication of NZ508981A publication Critical patent/NZ508981A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/70Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
    • C12Q1/701Specific hybridization probes
    • C12Q1/702Specific hybridization probes for retroviruses
    • C12Q1/703Viruses associated with AIDS

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • AIDS & HIV (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

A method of assessing the effectiveness of nucleoside reverse transcriptase antiretroviral therapy of an HIV- infected patient comprising evaluating whether a plasma sample from said HIV-infected patient contains a nucleic acid encoding HIV reverse transcriptase having a mutation/insertion at codon 69, wherein the presence of the mutation is correlated with decreased susceptibility to d4T.
NZ508981A 1998-06-24 1999-06-24 Means and methods for monitoring nucleoside reverse transcriptase inhibitor antiretroviral therapy and guiding therapeutic decisions in the treatment of HIV/AIDS NZ508981A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10429598A 1998-06-24 1998-06-24
PCT/US1999/014486 WO1999067427A1 (en) 1998-06-24 1999-06-24 Means and methods for monitoring nucleoside reverse transcriptase inhibitor antiretroviral therapy and guiding therapeutic decisions in the treatment of hiv/aids

Publications (1)

Publication Number Publication Date
NZ508981A true NZ508981A (en) 2004-02-27

Family

ID=22299700

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ508981A NZ508981A (en) 1998-06-24 1999-06-24 Means and methods for monitoring nucleoside reverse transcriptase inhibitor antiretroviral therapy and guiding therapeutic decisions in the treatment of HIV/AIDS

Country Status (9)

Country Link
EP (1) EP1015642A4 (en)
JP (1) JP2003503004A (en)
CN (1) CN1154747C (en)
AU (1) AU769927B2 (en)
BR (1) BR9912209A (en)
CA (1) CA2341679A1 (en)
MX (1) MXPA00012843A (en)
NZ (1) NZ508981A (en)
WO (1) WO1999067427A1 (en)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7037644B1 (en) 1998-05-26 2006-05-02 Virologic, Inc. Means and methods for monitoring non-nucleoside reverse transcriptase inhibitor antiretroviral therapy and guiding therapeutic decisions in the treatment of HIV/AIDS
JP2003501051A (en) 1999-05-28 2003-01-14 ビルコ・エヌ・ブイ Novel mutation profile in HIV-1 reverse transcriptase correlates with phenotypic drug resistance
US7186506B1 (en) 2000-06-12 2007-03-06 Monogram Biosciences, Inc. Means and methods for monitoring protease inhibitor antiretroviral therapy and guiding therapeutic decisions in the treatment of HIV/AIDS
US7138231B2 (en) 2000-09-15 2006-11-21 Monogram Biosciences, Inc. Means and methods for monitoring protease inhibitor antiretroviral therapy and guiding therapeutic decisions in the treatment of HIV/AIDS
US6869759B1 (en) 1999-06-22 2005-03-22 Virologic, Inc. Means and methods for monitoring protease inhibitor antiretroviral therapy and guiding therapeutic decisions in the treatment of HIV/AIDS
AU2007203337B2 (en) * 2000-04-18 2009-12-17 Virco Bvba Methods for measuring drug resistance
DE60135366D1 (en) 2000-04-18 2008-09-25 Virco Bvba METHOD FOR DETERMINING RESISTANCE TO MEDICAMENTS
US20040073378A1 (en) 2000-10-20 2004-04-15 Dehertogh Pascale Alfons Rosa Mutational profiles in hiv-1 reverse transcriptase correlated with phenotypic drug resistance
US6958211B2 (en) 2001-08-08 2005-10-25 Tibotech Bvba Methods of assessing HIV integrase inhibitor therapy
US7384734B2 (en) 2002-02-15 2008-06-10 Monogram Biosciences, Inc. Compositions and methods for determining the susceptibility of a pathogenic virus to protease inhibitors
ATE397669T1 (en) 2002-07-01 2008-06-15 Tibotec Pharm Ltd MUTATION PROFILES IN HIV-1 REVERSE TRANSCRIPTASE CORRELATED WITH PHENOTYPICAL DRUG RESISTANCE
CA2490862A1 (en) 2002-07-01 2004-01-08 Tibotec Pharmaceuticals Ltd. Mutational profiles in hiv-1 protease correlated with phenotypic drug resistance
TW200413720A (en) 2002-07-01 2004-08-01 Virologic Inc Compositions and methods for determining the susceptibility of a pathogenic virus to protease inhibitors
TW200411180A (en) 2002-07-01 2004-07-01 Virologic Inc Compositions and methods for determining the susceptibility of a pathogenic virus to protease inhibitors
WO2006089045A2 (en) 2005-02-18 2006-08-24 Monogram Biosciences, Inc. Methods and compositions for determining hypersusceptibility of hiv-1 to non-nucleoside reverse transcriptase inhibitors
EP1896618A4 (en) 2005-05-27 2009-12-30 Monogram Biosciences Inc METHOD AND COMPOSITIONS FOR DETERMINING THE RESISTANCE OF HIV-1 AGAINST PROTEASE INHIBITORS
WO2006133267A2 (en) 2005-06-06 2006-12-14 Monogram Biosciences, Inc. Methods and compositions for determining altered susceptibility of hiv-1 to anti-hiv drugs
US10480037B2 (en) 2011-09-23 2019-11-19 Laboratory Corporation Of America Holdings Methods and systems for predicting HIV-1 coreceptor tropism
CN103965302B (en) * 2013-01-29 2019-05-28 军事科学院军事医学研究院微生物流行病研究所 A kind of recombination super antigen SEB mutant, preparation method and application

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6087093A (en) * 1996-01-26 2000-07-11 Innogenetics N.V. Method for detection of drug-induced mutations in the reverse transcriptase gene
CA2216126C (en) * 1996-01-29 2009-03-31 Virologic, Inc. Compositions and methods for determining anti-viral drug susceptibility and resistance and anti-viral drug screening

Also Published As

Publication number Publication date
EP1015642A4 (en) 2005-03-23
WO1999067427A9 (en) 2000-03-30
EP1015642A1 (en) 2000-07-05
CN1154747C (en) 2004-06-23
JP2003503004A (en) 2003-01-28
CA2341679A1 (en) 1999-12-29
MXPA00012843A (en) 2002-04-24
CN1332804A (en) 2002-01-23
AU769927B2 (en) 2004-02-12
BR9912209A (en) 2002-11-05
AU4961199A (en) 2000-01-10
WO1999067427A1 (en) 1999-12-29

Similar Documents

Publication Publication Date Title
NZ508981A (en) Means and methods for monitoring nucleoside reverse transcriptase inhibitor antiretroviral therapy and guiding therapeutic decisions in the treatment of HIV/AIDS
AU2003263834A8 (en) Mutations in nod2 are associated with fibrostenosing disease in patients with crohn's disease
DE3853678D1 (en) METHOD FOR DETECTING THE CARCINOGENIC HUMAN PAPILLOMAVIRUS.
ATE442592T1 (en) DETECTION AND/OR MONITORING OF SYNUCLEIN-ASSOCIATED DISEASES
DE59813142D1 (en) DEVICE FOR DETECTING CATHETER TISSUE CONTACT AND INTERACTION WITH THE TISSUE IN CATHETER ABLATION
GB9716664D0 (en) A method of removing nucleic acid contamination reactions
DE3576853D1 (en) ULTRASONIC COAGULATION INDICATOR AND METHOD FOR DETECTING THE ENTERING OF COAGULATION.
ATE403750T1 (en) METHODS AND COMPOSITIONS FOR EVALUATION OF ANTIBODIES TREATMENTS
ATE190357T1 (en) RAPID METHOD FOR DNA SEQUENCING AND DIAGNOSTIC APPLICATIONS
AU2003302732A8 (en) Method for identifying risk of breast cancer and treatments thereof
NO920125L (en) PROCEDURE FOR AA DETERMINE THE FUNCTIONAL ACTIVITY TENT FOR FREE PROTEIN S OR PROTEIN C IN A PLASMA TEST
BR9906926A (en) Compositions and methods for treating cells having double minute dna
FR2611274B1 (en) AIDS DETECTION ASSEMBLY, AIDS RISK DETERMINATION METHOD, AND THERAPEUTIC COMPOSITION AGAINST THE SAME
WO2004043232A3 (en) Methods for identifying risk of melanoma and treatments thereof
EA200300846A1 (en) APPLICATION OF CD23 ANTAGONISTS FOR THE TREATMENT OF TUMOR DISEASES
ATE395433T1 (en) SCREENING PROCESS FOR SUITABLE ACTIVE INGREDIENTS
CA2202477A1 (en) Method, reagent and kit for evaluating susceptibility to premature atherosclerosis and treatment of same using gene therapy
WO2002022076A3 (en) Means and methods for monitoring protease inhibitor antiretroviral therapy and guiding therapeutic decisions in the treatment of hiv/aids
ATE169966T1 (en) METHOD AND DEVICE FOR STAINLESS STEEL STAINLESS STEEL
IL147294A0 (en) USE OF FVIIa OR A TISSUE FACTOR ANTAGONIST FOR REGUATING GENE EXPRESSION AND CELL MIGRATION OR CHEMOTAXIS
IL149398A0 (en) USE OF RUSSELL'S VIPER VENOM-INDUCED PLASMA FACTOR Xa ACTIVITY TO MONITOR THE ACTIVITY OF FACTOR Xa INHIBITORS
ATA8387A (en) DEVICE FOR HEAT TREATMENT, IN PARTICULAR GLOWING, OF A CONTINUOUSLY PROGRESSIVE METAL WIRE
DE69816585D1 (en) Method of examining metal composites using ultrasound
WO2002099387A3 (en) Means and methods for monitoring protease inhibitor antiretroviral therapy and guiding therapeutic decisions in the treatment of hiv/aids
ATE198219T1 (en) METHOD AND MEANS FOR ANALYZING GENETIC POLYMORPHISM OF ANGIOTENSIN CONVERSION ENZYME I

Legal Events

Date Code Title Description
RENW Renewal (renewal fees accepted)
PSEA Patent sealed
RENW Renewal (renewal fees accepted)